{"id":"fe958d56-d7f7-5739-831f-908a1dabb98b","stable_key":"788beb7b-7928-5f89-83d4-5556abf3702c:fulvic-acid-human-short-safety","predicate":"shows_short_term_tolerability","statement":"No severe adverse events were reported and measured safety parameters remained stable during the trial.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"59c816af-46e1-567a-8f14-49a380f160b6","mechanism_event_label":"This specified preparation was monitored for a short period.","subject":{"id":"5184fd06-5a8e-5e9d-99ec-c2feaa59ccde","slug":"carbohydrate-derived-fulvic-acid","display_name":"Carbohydrate-derived fulvic acid / CHD-FA (preparation class)","entity_type_key":"chemical_species"},"object":{"id":"9d4fe287-aa4e-505a-a4e3-d0423b6f4f8d","slug":"human-chdfa-phase1-safety","display_name":"Short-term safety observations in the CHD-FA phase-1 trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"59c816af-46e1-567a-8f14-49a380f160b6","stable_key":"788beb7b-7928-5f89-83d4-5556abf3702c:fulvic-acid-human-short-safety-event","event_type":"observed_relationship","label":"This specified preparation was monitored for a short period.","description":"No severe adverse events were reported and measured safety parameters remained stable during the trial.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5184fd06-5a8e-5e9d-99ec-c2feaa59ccde","slug":"carbohydrate-derived-fulvic-acid","display_name":"Carbohydrate-derived fulvic acid / CHD-FA (preparation class)","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9d4fe287-aa4e-505a-a4e3-d0423b6f4f8d","slug":"human-chdfa-phase1-safety","display_name":"Short-term safety observations in the CHD-FA phase-1 trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0aa6c0fc-8374-56e0-b172-6c40b6366d21","slug":"fulvic-acid","display_name":"Fulvic acid (heterogeneous humic fraction)","entity_type_key":"chemical_species"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Cannot establish chronic safety, pregnancy safety, safety in children, or equivalence of contaminated/environmental extracts.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Fulvic acid collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"fulvic-acid","display_name":"Fulvic acid (heterogeneous humic fraction)","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"This specified preparation was monitored for a short period.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22427734/ · DOI 10.2147/CPAA.S25784","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"532c9256-395b-55eb-81ed-c82c04f8ff82","evidence_kind":"source_excerpt","locator":"Lines 268-274","start_line":268,"end_line":274,"excerpt":"## fulvic-acid-human-short-safety\nThis specified preparation was monitored for a short period.\nNo severe adverse events were reported and measured safety parameters remained stable during the trial.\nModel: 30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment.\nLimitations: Cannot establish chronic safety, pregnancy safety, safety in children, or equivalence of contaminated/environmental extracts.\nEvidence access: Primary abstract\nPhase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22427734/ · DOI 10.2147/CPAA.S25784","model_system":"30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b00a1818-46e4-52cc-8dfe-a647d5c08ed7","stable_key":"import-788beb7b-7928-5f89-83d4-5556abf3702c","title":"Fulvic acid: mixture identity, mineral chemistry, signaling and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"52c2c3ee6bb23d943a40e1c39dd9de5cca7acd6efa72479cb824149e85cc7968","revision_id":"94dfc01b-c93e-55ff-8f48-bb2e9a1979f6","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}